Real data! A long-term study on the effects of smeglutide in weight loss

What are the ingredients and mechanism of action of Semagglutide?Semaglutide is a human glucagon like peptide-1 (GLP-1) analogue produced by brewing yeast cells through genetic recombination technology. Its chemical name is N ε 26 [(S) – (22, 40 dicarboxylic acid-10, 19…].
The mechanism of action of Semaglutide mainly includes the following aspects:
Promoting insulin synthesis and secretion: Semaglutide can bind to receptors on pancreatic beta cells, activate the cAMP/PKA and IP3 signaling pathways, thereby promoting insulin synthesis and secretion. In addition, it can stimulate the proliferation and differentiation of pancreatic beta cells, inhibit the apoptosis of pancreatic beta cells, increase the number of pancreatic beta cells, and have a protective effect on pancreatic function.
Inhibition of glucagon secretion: Semaglutide can inhibit the secretion of glucagon, thereby lowering blood sugar levels.
Reduce appetite and energy intake: Semaglutide mainly acts on the hypothalamus and posterior brain regions, stimulating the activity of neurons involved in appetite regulation in this area, thereby reducing appetite and energy intake.
Delaying gastric emptying: Semaglutide can also delay gastric emptying, further reducing food intake.
Multi organ and multi target mechanism of action: The hypoglycemic effect of Semaglutide is achieved through a multi organ and multi target mechanism of action, significantly improving beta cell function and insulin resistance, increasing insulin biosynthesis, and inhibiting glucagon secretion.
What are the clinical trial results of Smegglutide in weight loss?
The clinical trial results of Semaglutide in weight loss are as follows:
Oral Smegglutide:
After 68 weeks of treatment with a daily dose of 50mg oral semaglutide combined with lifestyle intervention, overweight or obese adult patients participating in the trial showed superior and clinically significant weight loss compared to placebo.
After 52 weeks of treatment, the weight loss was 5.2 kilograms after oral administration of 14 milligrams of sitagliptin tablets (once a day).
In the OASIS 1 trial, oral administration of 50 mg of smeglutide achieved 15.1% weight loss in obese and overweight patients (17.4% in fully compliant patients).
Injection Smegglutide:
After 68 weeks of treatment with Semaglutide Injection (2.4 mg, once a week), weight loss of approximately 15.3 kilograms can be achieved.
In the STEP 1 trial, the effect of injecting 2.4 mg of smeglutide on obesity was comparable to that of the oral version.
Side effects and safety assessment report of long-term use of Smegglutide.
Semaglutide is a drug used to treat overweight, obesity and type 2 diabetes, with significant weight loss and cardiovascular health benefits. However, long-term use of this drug also comes with some side effects and potential risks.
side effect
Gastrointestinal reactions: The most common side effects include gastrointestinal discomfort such as nausea, vomiting, diarrhea, and constipation. These symptoms usually appear in the early stages of treatment and may alleviate over time.
Injection site reaction: The injection site may experience redness, swelling, and fatigue.
Hypoglycemia: Although the risk of hypoglycemia is small when Semaglutide is used alone, hypoglycemic events may occur in patients with type 2 diabetes when it is used in combination with sulfonylurea drugs or insulin.
Other adverse reactions: including redness, swelling, fatigue, diarrhea, constipation, etc. at the injection site.
Security assessment
Serious Adverse Events (SAE): In a study, 13.3% of participants in the Semaglutide group reported serious adverse events, while 26.7% in the placebo group, indicating a relatively high safety profile of Smegglutide.
Thyroid and pancreatic problems: Animal experiments have found that smectide can stimulate the proliferation of thyroid C cells, so it is contraindicated for patients with medullary thyroid carcinoma. In addition, because it may induce pancreatic cancer, people with high triglycerides are not recommended to use it.
Liver function impact: In the Phase 2 trial of non-alcoholic steatohepatitis related cirrhosis patients, safety assessments were conducted on all patients who received at least one dose of the study drug, but specific results were not explicitly mentioned.
conclusion
Although Semaglutide has shown significant therapeutic effects in weight loss and cardiovascular health, its long-term side effects and potential risks cannot be ignored. Doctors and patients should conduct a comprehensive evaluation and monitoring when using this medication to ensure its safety and effectiveness.
Comparison of the effects of Smegglutide compared to other weight loss drugs.
Compared with other weight loss drugs, there are certain differences in the effectiveness of emaglutide.
Comparison with CagriSema: After treatment with CagriSema (Semaglutide+Cargliptin), the average weight loss of patients was 15.6%, with more than half of patients losing ≥ 15% of their weight. The weight loss effect was better than using Semaglutide alone.
Comparison with Liraglutide: In one study, at week 64, semaglutide lost 15.8% of weight, while Liraglutide lost only 6.4% during the same period.
Comparison with Telposide: Clinical studies have shown that Telposide is more effective in reducing HbA1c and weight, and therefore has the potential to become the “strongest opponent” of Smegglutide.
Comparison with other GLP-1 drugs: Several meta-analyses have compared the efficacy of different GLP-1RA, showing that the weight loss effect of semaglutide has been comprehensively surpassed.